supported bythe National Natural Science Foundation of China(No.30870822)
Objective Letrozole, a next-generation aromatase inhibitor, has become a favored drug for the treatment of breast cancer in postmenopausal women. Although letrozolc is generally well tolerated, its adverse effects on ...